Welcome to our dedicated page for Curtiss Wright SEC filings (Ticker: CW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Curtiss-Wright Corporation (NYSE: CW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Curtiss-Wright is a global integrated business that supplies highly engineered products, solutions and services mainly to aerospace and defense markets, and critical technologies in commercial nuclear power, process and industrial markets. Its filings offer detailed insight into how these activities translate into financial results, risks and capital allocation decisions.
Through periodic reports such as Form 10-K and Form 10-Q, Curtiss-Wright presents segment information for Aerospace & Industrial, Defense Electronics, and Naval & Power, along with discussions of total aerospace and defense markets and total commercial markets. These documents typically include data on sales, operating income, operating margin, new orders, backlog and free cash flow, as well as commentary on factors such as product mix, restructuring initiatives and operational excellence programs.
Current reports on Form 8-K provide updates on specific events, including quarterly and annual earnings releases, changes to financial guidance, adoption of Rule 10b5-1 trading plans for share repurchases, and expansions of repurchase authorizations. These filings describe how Curtiss-Wright structures its repurchase programs, the amounts authorized, and the expected timing of purchases under those plans.
Stock Titan enhances access to these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand segment performance, capital allocation actions and notable risk disclosures. Real-time updates from EDGAR, along with visibility into relevant forms such as 10-K, 10-Q and 8-K, allow investors and researchers to review Curtiss-Wright’s regulatory history and ongoing reporting in a structured, easy-to-navigate format.
CW filed a Form 144 reporting a proposed sale of 1,265 shares of Common Stock through UBS Financial Services (NYSE) tied to an RSU vesting on 03/16/2026.
The filing names K. Christopher Farkas and lists prior dispositions in the past three months: 3,105 shares sold on 02/18/2026 for $2,156,439.58 and 2,665 shares sold on 02/04/2026 for $1,669,034.61.
Curtiss-Wright EVP & Chief Growth Officer John C. Watts exercised 512 restricted stock units into common shares and sold 220 shares. The RSUs were granted on March 16, 2023 under the 2014 Omnibus Incentive Plan and cliff vested after a three-year period.
The 220 common shares were sold on the open market at an average price of $678.11 per share, in multiple trades between $671.53 and $681.02. According to the disclosure, the sale was made to cover tax obligations related to the vesting, and Watts remains in compliance with the company’s share ownership guidelines.
Following these transactions, Watts directly holds 4,182 shares of Curtiss-Wright common stock and 895 restricted stock units, including dividend credits earned on prior grants.
Form 144 filing reports proposed dispositions of Common Stock linked to RSUs for CW. The filing lists an intended sale reported through UBS Financial Services and shows prior dispositions by Gary Ogilby: $272,427.46 for 02/04/2026 (435 shares), $272,400.00 for 02/03/2026 (435 shares), and $100,300.00 for 03/17/2026 (148 shares). The filing date appears as 03/18/2026.
Curtiss-Wright Senior VP & Treasurer Robert F. Freda reported equity award vesting and a small share sale. On March 16, 2026, 296 restricted stock units granted on March 16, 2023 under the 2014 Omnibus Incentive Plan cliff vested and converted into common stock at a $0.00 exercise price.
On March 17, 2026, he sold 140 shares of common stock in open-market transactions at an average price of $678.61 per share. Footnotes explain the sale was made to cover tax obligations in line with company share ownership guidelines, and that he remains in compliance. After the transactions, he directly holds 5,343 common shares, including dividend credits on prior grants.
Curtiss-Wright Senior VP & Corp Controller Gary A. Ogilby reported a combination of equity vesting and a small share sale. On March 16, 2026, 400 shares of common stock were acquired at $0.00 per share through the vesting and conversion of restricted stock units granted in 2023 under the company’s 2014 Omnibus Incentive Plan. On March 17, 2026, he sold 148 shares of common stock at an average price of $678.30 per share. Footnotes state the sale was made to cover tax obligations associated with the vesting and that he remains in compliance with the company’s share ownership guidelines. Following these transactions, he directly holds 2,823 shares of common stock and 4,420 restricted stock units, including dividend credits.
Curtiss-Wright executive George P. McDonald reported routine equity compensation activity, including an RSU vesting and a small share sale. On March 16, 2026, 350 restricted stock units granted on March 16, 2023 vested and were converted into 350 shares of common stock under the company’s 2014 Omnibus Incentive Plan, with no exercise price as they were granted as an employee benefit.
On March 17, 2026, he sold 151 shares of common stock in open-market transactions at an average price of $678.07 per share. A footnote explains the sale was made in line with Curtiss-Wright’s share ownership guidelines, allowing a portion of the vesting award to be sold to cover tax obligations from the vesting, and states he remains in compliance with those guidelines. After these transactions, he directly holds 4,210 shares of common stock and 1,112 restricted stock units, with share totals including dividend credits on prior grants.
Curtiss-Wright Executive VP and COO Kevin Rayment exercised 2,504 restricted stock units into the same number of common shares on March 16, 2026, stemming from a March 16, 2023 RSU grant that cliff-vested after three years.
On March 17, 2026, he completed an open-market sale of 907 common shares at an average price of $677.38 per share, with trades executed between $671.52 and $681. The company notes these shares were sold in line with share ownership guidelines to cover tax obligations related to the vesting. Following the transactions, Rayment directly holds 31,493 common shares and 3,928 RSUs, including dividend credits.
Curtiss-Wright Executive VP and CFO Christopher K. Farkas reported the vesting of restricted stock units and a related share sale. On March 16, 2026, 2,183 restricted stock units granted on March 16, 2023 under the 2014 Omnibus Incentive Plan cliff vested into common stock with no exercise price as an employee benefit.
Following vesting, he held 6,436 common shares, then on March 17, 2026 he sold 918 common shares in open-market transactions at an average price of $677.46 per share. The sale was made to cover tax obligations associated with the vesting, in line with company share ownership guidelines, and left him with 5,518 common shares and 9,366 restricted stock units, including dividend credits.
Curtiss-Wright Chair and CEO Lynn M. Bamford reported a routine combination of RSU vesting and share sale. On March 16, 2026, 7,667 restricted stock units granted on March 16, 2023 under the 2014 Omnibus Incentive Plan cliff vested into common stock at no cash exercise price as an employee benefit. Following this, she held 14,614 RSUs, including dividend credits. On March 17, 2026, she executed an open-market sale of 3,225 common shares at an average price of $676.70 per share, with individual trades ranging from $669.05 to $681. The footnotes state these shares were sold in line with company share ownership guidelines to cover tax obligations from the vesting, and that she remains in compliance. After the sale, she directly owns 50,634 common shares.
CW: A Form 144 notice lists an intended sale of 907 shares of Common Stock tied to restricted stock vesting with an event date of 03/16/2026. The filing also reports 2,634 shares sold during the past three months on 02/04/2026 by Kevin Rayment.